Get the Stockscreener App
0.4457
4.91%
-0.023
Gt Biopharma Inc stock is traded at $0.4457, with a volume of 1.28M.
It is down -4.91% in the last 24 hours and up +13.15% over the past month.
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.
See More
Previous Close:
$0.4687
Open:
$0.48
24h Volume:
1.28M
Relative Volume:
1.03
Market Cap:
$16.07M
Revenue:
-
Net Income/Loss:
$-47.73M
P/E Ratio:
-0.031
EPS:
-14.3996
Net Cash Flow:
$-13.18M
1W Performance:
+6.63%
1M Performance:
+13.15%
6M Performance:
-38.10%
1Y Performance:
-84.20%
1-Day Range:
$0.4418
$0.4818
1-Week Range:
$0.3911
$0.4867
52-Week Range:
$0.261
$3.85
Gt Biopharma Inc Stock (GTBP) Company Profile
Name
Gt Biopharma Inc
Sector
Industry
Phone
(800) 304-9888
Address
505 MONTGOMERY STREET, SAN FRANCISCO
Compare GTBP vs MOBBW, SHMD, GOODO, PSNYW, DWLD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 0.2846 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
2.45 | 3.33B | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
6.19 | 397.06M | 52.15M | -21.46M | 0 | -0.4675 |
GOODO
Gladstone Commercial Corporation
|
20.19 | 372.90M | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
2.83 | 254.39M | 2.07B | -1.42B | -1.37B | -0.6765 |
DWLD
Davis Select Worldwide ETF
|
47.19 | 0 | 0 | 0 | 0 | 0.00 |
Gt Biopharma Inc Stock (GTBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-24 | Initiated | ROTH MKM | Buy |
| May-24-21 | Initiated | H.C. Wainwright | Buy |
| Apr-13-21 | Initiated | B. Riley Securities | Buy |
| Mar-17-21 | Initiated | ROTH Capital | Buy |
Gt Biopharma Inc Stock (GTBP) Latest News
GT Biopharma, Inc. Announces Amendment to Bylaws in June 2026 SEC Form 8-K Filing - Minichart
GTBP Q1 2026 Earnings: Wider-than-Expected Loss but Stock GainsForward Guidance Trends - newsline.com
GT Biopharma Lowers Stockholder Quorum to One-Third - TipRanks
GT BIOPHARMA INC (GTBP) Stock Chart - ChartMill
GT Biopharma (NASDAQ: GTBP) lowers meeting quorum to one-third - Stock Titan
After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell - GlobeNewswire
GT Biopharma stock (US36254L1098): FDA green light for new TriKE program puts focus on pipeline - AD HOC NEWS
Three Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE Bet - The Manila Times
GT Biopharma, Inc. - MLQ.ai
GTBP Q1 2026 Earnings: EPS Miss Weighs on Sentiment as Biotech Advances PipelineQuarterly Earnings Report - newsline.com
Precision Oncology Platforms Converge as FDA Accelerates Treatment Innovation - Baystreet.ca
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company - The Globe and Mail
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company - Benzinga
GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives - The Manila Times
GT Biopharma Provides Update on Pipeline Discovery - GlobeNewswire
EXCLUSIVE: GT Biopharma Sees Faster Discovery, Productivity Following AI Technology Rollout - Benzinga
How GT Biopharma is using AI to shrink drug timelines and costs - Stock Titan
GT Biopharma Inc stock (US36254L1098): Nasdaq micro-cap edges lower ahead of valuation focus - AD HOC NEWS
The $13 Million Company Teaching the Immune System to Hunt Cancer - Quantisnow
SEC Says Former GT Biopharma CEO Used Cancer Research Funds to Buy Beverly Hills Mansion - gritdaily.com
GT Biopharma (GTBP) Maintains Support Zone Amid Modest UptickNew Listing Stocks - newsline.com
GT Biopharma Inc. (GTBP) Falls Over 10% as Biotech Sentiment WeakensADD Alert - The Legal Advocate
GT Biopharma Q1 2026 Earnings: Wider-than-Expected Loss Amid Continued DevelopmentProfit Cycle Analysis - newsline.com
GT Biopharma, Inc. 8-K Filing: Nasdaq Compliance, Company Details & Key Disclosures (May 20, 2026) 10 - Minichart
GT Biopharma receives 180-day extension from Nasdaq to meet minimum bid price By Investing.com - Investing.com South Africa
GT Biopharma receives 180-day extension from Nasdaq to meet minimum bid price - Investing.com
GT Biopharma Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Nasdaq grants GT Biopharma (NASDAQ: GTBP) 180-day minimum bid reprieve - Stock Titan
GT Biopharma Edges Higher, Testing Key Resistance at $0.45Community Watchlist Picks - Newser
GT Biopharma Q1 2026 Earnings: Wider-Than-Expected Loss Amid Strategic Pipeline UpdatesEarnings Power Value - Newser
GT Biopharma Inc stock (US36254L1098): new B7-H3 TriKE enters the clinic and puts NK cell engagers i - AD HOC NEWS
Exclusive: GT Biopharma begins testing of lead solid tumor drug candidate across multiple cancer types - MSN
B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic - Sahm
Why Is GT Biopharma, Inc. (GTBP.PA) Stock Down Today? - Meyka
GT Biopharma Inc stock (US36254L1098): clinical pipeline and stock under pressure after recent finan - AD HOC NEWS
Key facts: GT Biopharma Q1 Loss $2.83M; Nasdaq Listing at Risk - TradingView
GT Biopharma, Inc. Q1 2026 Financial Results: Quarterly Report, Financial Statements, and Key Disclosures - Minichart
GTBP Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
GT Biopharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
GT Biopharma Reports First Quarter 2026 Financial Results - The Manila Times
GT Biopharma, Inc. 1Q 2026: Net loss $(2.83M), Revenue $0— 10-Q Summary - TradingView
GT Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
[10-Q] GT Biopharma, Inc. Quarterly Earnings Report - Stock Titan
GTBP Q1'26 Earnings: EPS estimate is (0.08) USD - TradingView
First Patient Dosed in Phase 1 Trial Marks Expansion of NK Cell Engager Platform Into Solid Tumors - Baystreet.ca
GT Biopharma stock (US36254L1098): First patient dosed in solid tumor trial - AD HOC NEWS
GT Biopharma Inc - Menafn.com
A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology - Toronto Star
GT Biopharma doses first patient in solid tumor trial By Investing.com - Investing.com South Africa
GT Biopharma announces first patient dosed in phase 1 trial of GTB-5550, a B7-H3-targeted natural killer (NK) cell engager for solid tumors - marketscreener.com
GT Biopharma doses first patient in solid tumor trial - Investing.com India
Gt Biopharma Inc Stock (GTBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):